BankPlus Trust Department’s Vertex Pharmaceuticals VRTX Stock Holding History

BankPlus Trust Department’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$640K	Buy	1,433 +77	+6%	+$35.9K	0.17%	111
2025 Q4	$615K	Buy	1,356 +33	+2%	+$14.2K	0.16%	108
2025 Q3	$518K	Sell	1,323 -18	-1%	-$7.52K	0.14%	117
2025 Q2	$597K	Sell	1,341 -15	-1%	-$6.91K	0.18%	99
2025 Q1	$657K	Sell	1,356 -23	-2%	-$10.7K	0.22%	86
2024 Q4	$555K	Buy	+1,379	New	+$639K	0.18%	98

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BankPlus Trust Department's VRTX Position: Q1 2026 in Review

BankPlus Trust Department increased its Vertex Pharmaceuticals (VRTX) stake by 5.7% in Q1 2026, buying an estimated $35.9K and bringing the position to 1,433 shares worth $640K. The position accounts for 0.17% of the portfolio, ranked #111.

BankPlus Trust Department first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $657K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

BankPlus Trust Department held 1,433 shares of Vertex Pharmaceuticals worth $640K as of Q1 2026.
BankPlus Trust Department bought 77 Vertex Pharmaceuticals shares in Q1 2026, an estimated $35.9K.
Vertex Pharmaceuticals made up 0.17% of BankPlus Trust Department's portfolio in Q1 2026, its #111 holding.
BankPlus Trust Department first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
BankPlus Trust Department's Vertex Pharmaceuticals position peaked at $657K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on BankPlus Trust Department's 13F filing for Q1 2026, filed 11 May 2026.